YUMAB The success of next genera-
tion antibody drug development relies
on comprehensive discovery technolo-
gies and strategies.
VHH discovery for bispecifics – combination of in-vivo immunization and in-vitro display
Conventional IgG antibodies are powerful tools for many
applications. Despite their flexibility, they also encounter limits of
feasibility. With their size of 150 kDa they are limited in tissue
penetration and less stable when it comes to harsh conditions, such as
pH stress, temperature stress or protease rich environments, just to
name a few.
Single domain antibodies (e.g. VHH) possess properties which circumvent these limitations. This case study demonstrates the power of YUMAB’s VHH discovery platform by combining in-vivo immunization and in-vitro display.
